Biosimilars are biological products that are replicas of their innovative biopharmaceuticals. These are developed after patent expiration of innovator biopharmaceuticals and are submitted for separate marketing approval. The rise of biological drugs has driven the increased use of drug delivery devices that can better support subcutaneous self-administration of these drugs for chronic diseases. Although originally a source of differentiation, autoinjectors have now become a market expectation in many disease areas, so it is not surprising that the biosimilars market companies have frequently chosen to follow suit when entering the market. The expiry of patent protection of many biopharmaceuticals has initiated the development of a category of alternative versions of innovator biopharmaceuticals known as biosimilars.

Innovation through drug delivery technology has been a common defense mechanism for the originator biopharma companies against biosimilars. Owing to affordability and easy accessibility, biosimilars have established a good reputation among healthcare professionals. Biotechnological medicines shall become an important part of the future healthcare landscape. With the patent expiration of innovator products, the biosimilar market products will increasingly become available. With a strong focus on price reduction and increasing competition amongst biosimilars for the same reference drug, biosimilar manufacturers have tended to focus on cost reduction through manufacturing efficiency.

Author’s Bio:

Anthena John:

Senior Market Research expert at The Insight Partners